Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Sovleplenib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    HUTCHMED Highlights Sovleplenib, Hematology Data At Upcoming EHA 2024
    HUTCHMED Highlights Sovleplenib, Hematology Data At Upcoming EHA 2024

    16 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/17/2883983/0/en/HUTCHMED-Highlights-Sovleplenib-Phase-III-ESLIM-01-Study-and-Hematological-Malignancy-Programs-Data-to-be-Presented-at-the-upcoming-EHA2024-Congress.html

    GLOBENEWSWIRE
    16 May 2024
    Share Share
    Hutchmed Announces NDA Acceptance in China for Sovleplenib
    Hutchmed Announces NDA Acceptance in China for Sovleplenib

    10 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/11/2807571/0/en/HUTCHMED-Announces-NDA-Acceptance-in-China-for-Sovleplenib-for-the-Treatment-of-Primary-Immune-Thrombocytopenia-with-Priority-Review-Status.html

    GLOBENEWSWIRE
    10 Jan 2024
    Share Share
    Sovleplenib Elicits Durable Responses in Primary Immune Thrombocytopenia
    Sovleplenib Elicits Durable Responses in Primary Immune Thrombocytopenia

    24 Aug 2023

    // ONCLIVE

    https://www.onclive.com/view/sovleplenib-elicits-durable-responses-in-primary-immune-thrombocytopenia

    ONCLIVE
    24 Aug 2023
    Share Share
    HUTCHMED Announces that Sovleplenib PIII ESLIM-01 Study Met Its Primary Endpoint
    HUTCHMED Announces that Sovleplenib PIII ESLIM-01 Study Met Its Primary Endpoint

    21 Aug 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/08/21/2728359/0/en/HUTCHMED-Announces-that-the-Sovleplenib-Phase-III-ESLIM-01-Study-Met-Its-Primary-Endpoint-in-Primary-Immune-Thrombocytopenia-in-China.html

    GLOBENEWSWIRE
    21 Aug 2023
    Share Share
    HUTCHMED Completes Patient Enrollment of ESLIM-01, a Ph III Trial of Sovleplenib
    HUTCHMED Completes Patient Enrollment of ESLIM-01, a Ph III Trial of Sovleplenib

    03 Jan 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/01/03/2581851/0/en/HUTCHMED-Completes-Patient-Enrollment-of-ESLIM-01-a-Phase-III-Trial-of-Sovleplenib-in-Primary-Immune-Thrombocytopenia-in-China.html

    GLOBENEWSWIRE
    03 Jan 2023
    Share Share